V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 20213276 | 20079748 | 1.72 | 0 | Palliative (P) | 2018-01-23 | 2018-01-25 | Cape+Cisplatin+Trastuzumab Main | 02 | N | TRIAL | 100719364 |
| 20213277 | 20079749 | 1.6 | 77.4 | Adjuvant (A) | 2019-01-23 | 2019-01-25 | Imatinib 400mg | 02 | N | IMATINIB | 101798217 |
| 20213278 | 20079750 | null | null | Palliative (P) | 2019-02-19 | 2019-02-20 | LANREOTIDE | 02 | N | LANREOTIDE | 101528157 |
| 20213280 | 20079751 | 1.8 | 104.5 | Curative (C) | 2016-07-01 | 2016-07-01 | Cetuximab + FLUOROURACIL + FOLINIC ACID + IRINOTECAN | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 100864249 |
| 20213282 | 20079752 | 1.62 | 86.2 | null | 2019-10-10 | 2019-10-17 | LANREOTIDE | 02 | null | LANREOTIDE | 101138780 |
| 20213283 | 20079753 | 1.6 | 85.7 | Neo-adjuvant (N) | 2016-08-26 | 2016-09-02 | Cetuximab + FOLFIRI cycle 2 onwards | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 101030471 |
| 20213286 | 20079755 | 1.78 | 92.4 | Palliative (P) | 2018-01-10 | 2018-02-05 | Cetuximab + FLUOROURACIL + FOLINIC ACID + IRINOTECAN | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 100006433 |
| 20213287 | 20079756 | 1.82 | 73.5 | Palliative (P) | 2019-05-18 | 2019-06-07 | Cape+Cisplatin+Trastuzumab Load | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 101222662 |
| 20213288 | 20079757 | 1.88 | 0 | Palliative (P) | 2017-07-02 | 2017-07-02 | Trial Unspecified | Y | N | TRIAL | 101177757 |
| 20213289 | 20079758 | 1.83 | 78.3 | Palliative (P) | 2016-10-29 | 2016-11-06 | HCX (Cape + Cisp + Tras) - Load | 02 | null | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100994229 |
| 20213291 | 20079759 | 1.66 | 73.6 | Palliative (P) | 2019-06-13 | 2019-06-17 | CETUXIMAB + IRINOTECAN + MDG | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 101293651 |
| 20213292 | 20079760 | 1.67 | 54.3 | Palliative (P) | 2017-02-26 | 2017-03-25 | Cetuximab + FLUOROURACIL + FOLINIC ACID + IRINOTECAN | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 100853851 |
| 20213294 | 20079762 | 1.59 | 87 | Palliative (P) | 2019-04-10 | 2019-04-10 | Trial Unspecified | null | N | TRIAL | 101164992 |
| 20213295 | 20079763 | 1.67 | 56.6 | null | 2018-09-08 | 2018-09-09 | Imatinib 400mg | 2 | null | IMATINIB | 100716915 |
| 20213296 | 20079764 | 1.56 | 81.9 | Palliative (P) | 2016-04-08 | 2016-04-17 | HCX (Cape + Cisp + Tras) - Load | null | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100440160 |
| 20213298 | 20079765 | 1.64 | 67.1 | Palliative (P) | 2020-01-08 | 2020-01-25 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101746436 |
| 20213300 | 20079766 | 1.7 | 76.8 | null | 2018-01-16 | 2018-02-06 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | null | LANREOTIDE | 101594974 |
| 20213302 | 20079767 | null | null | 03 | 2016-10-23 | 2016-10-23 | LANREOTIDE | 02 | N | LANREOTIDE | 100082793 |
| 20213303 | 20079768 | 1.59 | 64.1 | Palliative (P) | null | 2018-12-26 | Cape+Cisplatin+Trastuzumab Load | 02 | N | TRIAL | 100475204 |
| 20213304 | 20079769 | 1.78 | 85 | Palliative (P) | 2020-03-24 | 2020-04-07 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | TRIAL | 101134107 |
| 20213305 | 20079770 | 1.67 | 74 | null | 2016-11-17 | 2016-11-17 | LANREOTIDE | 02 | null | LANREOTIDE | 100266986 |
| 20213306 | 20079771 | 0 | 46.1 | null | 2018-08-14 | 2018-08-14 | LANREOTIDE | 99 | N | LANREOTIDE | 100677639 |
| 20213307 | 20079772 | null | 88 | Palliative (P) | 2018-08-16 | 2018-08-16 | LANREOTIDE | 02 | N | LANREOTIDE | 101513082 |
| 20213308 | 20079773 | 1.54 | 58.8 | Palliative (P) | 2017-07-12 | 2017-08-14 | HCX (Cape + Cisp + Tras) - Load | 02 | N | IMATINIB | 100286853 |
| 20213311 | 20079774 | null | 46.3 | 03 | 2018-02-02 | 2018-02-09 | LANREOTIDE | 02 | N | LANREOTIDE | 101579319 |
| 20213312 | 20079775 | 1.84 | 80 | Palliative (P) | 2016-10-19 | 2016-11-01 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100637707 |
| 20213313 | 20079776 | 1.71 | 72.5 | Palliative (P) | 2019-04-24 | 2019-05-08 | HCX (Cape + Cisp + Tras) - Main | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101352390 |
| 20213316 | 20079778 | 1.69 | 72.2 | Curative (C) | 2018-02-16 | 2018-02-28 | FLUOROURACIL + MITOMYCIN + RT | N | Y | FLUOROURACIL + MITOMYCIN + RT | 100094673 |
| 20213317 | 20079779 | 1.74 | 0 | null | 2019-07-05 | 2019-07-05 | Cape+Cisplatin+Trastuzumab Load | 02 | null | LANREOTIDE | 101512520 |
| 20213318 | 20079780 | 1.83 | 83.5 | Palliative (P) | 2016-12-14 | 2016-12-14 | Cetuximab + FOLFIRI cycle1 | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 101703723 |
| 20213319 | 20079781 | 1.83 | 114 | null | 2016-11-14 | 2016-11-16 | IMATINIB | 02 | null | IMATINIB | 100973323 |
| 20213320 | 20079782 | 1.5 | 61.8 | Palliative (P) | 2019-03-30 | 2019-04-12 | Cape+Cisplatin+Trastuzumab Load | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101384205 |
| 20213321 | 20079783 | null | 98.2 | Curative (C) | null | 2018-11-05 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | Y | FLUOROURACIL + MITOMYCIN + RT | 101242335 |
| 20213322 | 20079784 | null | 94.3 | null | 2018-12-01 | 2018-12-12 | LANREOTIDE | 02 | null | LANREOTIDE | 101252766 |
| 20213323 | 20079785 | 1.59 | 81.3 | Curative (C) | 2019-02-10 | 2019-03-18 | Cape+Cisplatin+Trastuzumab Load | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 101170129 |
| 20213325 | 20079787 | 1.76 | 64 | Palliative (P) | 2018-08-29 | 2018-09-18 | Cetuximab + FOLFIRI cycle 2 onwards | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 100602091 |
| 20213326 | 20079788 | 1.56 | 61 | Palliative (P) | 2017-08-09 | 2017-08-13 | Trial Unspecified | 01 | N | TRIAL | 100777964 |
| 20213327 | 20079789 | 1.56 | 95.6 | Curative (C) | null | 2016-03-22 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | Y | FLUOROURACIL + MITOMYCIN + RT | 101521341 |
| 20213328 | 20079790 | 1.61 | 61.3 | Palliative (P) | 2019-08-19 | 2019-09-12 | CETUXIMAB + IRINOTECAN + MDG | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 100881088 |
| 20213329 | 20079791 | 1.78 | 92 | Curative (C) | null | 2018-05-22 | Fluorouracil+Mitomycin+RT (Anal Ca) | 2 | N | FLUOROURACIL + MITOMYCIN + RT | 101809902 |
| 20213330 | 20079792 | 1.53 | 62 | Palliative (P) | 2016-08-05 | 2016-08-12 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100724661 |
| 20213332 | 20079793 | 1.8 | 74.81 | Palliative (P) | 2018-12-19 | 2018-12-26 | Trial Unspecified | Y | N | TRIAL | 101812052 |
| 20213334 | 20079794 | 1.69 | 87 | null | 2017-02-09 | 2017-02-09 | Imatinib 400mg | 02 | null | IMATINIB | 100095536 |
| 20213335 | 20079795 | 1.78 | 75 | null | 2019-09-29 | 2019-10-12 | CETUXIMAB + IRINOTECAN + MDG | 02 | null | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 100553447 |
| 20213339 | 20079798 | 1.7 | 49.4 | Curative (C) | 2019-01-20 | 2019-01-20 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | Y | FLUOROURACIL + MITOMYCIN + RT | 100417653 |
| 20213340 | 20079799 | 1.79 | 71.8 | null | 2020-06-23 | 2020-07-23 | HCX (Cape + Cisp + Tras) - Main | 02 | null | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 100480454 |
| 20213341 | 20079800 | 0 | 69.4 | null | 2021-04-18 | 2021-04-18 | Imatinib 400mg | 02 | null | IMATINIB | 101500224 |
| 20213342 | 20079801 | 1.8 | 61.8 | Curative (C) | 2018-04-02 | 2018-04-16 | Fluorouracil+Mitomycin+RT (Anal Ca) | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 101168720 |
| 20213344 | 20079802 | 1.75 | 0 | Curative (C) | 2017-04-13 | 2017-04-29 | Cape+Cisplatin+Trastuzumab Load | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 100499929 |
| 20213345 | 20079803 | 1.58 | 61.6 | null | 2016-09-02 | 2016-09-20 | HCX (Cape + Cisp + Tras) - Main | 02 | null | IMATINIB | 101509499 |